Forbion Capital Raises $50 Million to Invest in Health Companies

Forbion Capital Partners raised about $50 million for a second fund to invest in health-care companies that are close to being sold.

The fund made its first investment in CircuLite Inc., a U.S. developer of devices to treat heart failure, the Dutch firm said in an e-mailed statement today.

Forbion’s first FCF 1 Co-Investment Fund, which raised 54 million euros ($72 million), has made six investments. One of those companies, BioVex Group Inc., was purchased by Amgen Inc. (AMGN) in January for as much as $1 billion. Another company in Forbion’s portfolio, Pathway Medical Technologies Inc., was sold in September to Bayer AG (BAYN) for $125 million, the firm said.

“We raised this second FCF 1 Co-Investment Fund in just a few weeks in difficult markets,” Sander Slootweg, a managing partner at Forbion, said in the statement.

To contact the reporter on this story: Kristen Hallam in London at

To contact the editor responsible for this story: Phil Serafino at

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.